Abstracts

Single Dose Administration of MK-8527, a Novel nRTTI, in Adults With HIV-1

Background: MK-8527 is a novel oral nucleoside reverse transcriptase translocation inhibitor (NRTTI) under clinical development as an antiretroviral for HIV-1 infection. Based on previous preclinical and phase 1 clinical studies, the pharmacokinetic properties of MK-8527 support extended once-weekly or longer dosing. Two phase 1 single dose monotherapy studies were conducted to evaluate the antiretroviral activity…

Mini-Lecture on HIV Persistence in the CNS: Considerations for Current Cure Strategies

Presentation: The central nervous system (CNS) presents a unique challenge for HIV cure strategies given the diverse infected cells that persist on antiretroviral therapy (ART) – including infected microglia, astrocytes and circulating T-cells, as well as the presence of the blood brain barrier (BBB), and the adverse acute and chronic consequences of localised inflammation. Numerous…

Low Levels of HIV-1 in CSF During ART Are Associated With Neurocognitive Impairment and Inflammation

Background: Antiretroviral therapy (ART) typically reduces HIV-1 RNA to below the limit of detection of standard vial load (VL) assays and facilitates immune reconstitution, but neurocognitive impairment (NCI) persists in many people on ART. Previous studies have suggested that higher HIV-1 cell-associated DNA and cell-free RNA levels in cerebrospinal fluid (CSF) are positively associated with…

MHC-E Presentation Mediates SIV-Specific NK Cell Responses in SIV-Infected Rhesus Macaques

Background: Natural killer (NK) cells provide rapid and robust responses against viral infections. Multiple studies have shown that NK cells are also capable of antigen-specific recall to eliminate infected cells. In nonhuman primates (NHP), antigen-specific memory-like NK cell can be designed by MHC-E dependent response. During SIV infection, the stabilized MHC-E molecule may induce a…

Multi-Specificity Is a Common Trait of HIV-1 Broad Neutralizing Capacity

Background: Multi-specific responses have been described in rare people who evolved broadly neutralizing antibody (bnAb) activity in HIV-1 infection but their relevance remains unclear. Here we screened the Swiss HIV Cohort Study for multi-specificity by examining the XbnAb cohort comprising bnAb inducers (N=304) identified in the Swiss 4.5k Screen (Rusert Nat Med 2016). Methods: Plasma…

CD4 Binding Site Glycan-Deficient SHIVs Elicit Broadly Neutralizing Antibodies in Rhesus Macaques

Background: Previous work has demonstrated that modifying soluble HIV-1 envelope (Env) trimers to remove glycans around the CD4 binding site (CD4bs) can immunofocus potent neutralizing antibody (NAb) responses to this epitope. However, such immunogens generally did not elicit broadly neutralizing antibodies (bNAbs). Understanding how to better boost these responses can inform vaccine design. Infection of…

Safety Profile and Immunogenicity of a Phase I Clinical Trial Using Germline-Targeting Trimer GT1.1

Background: An effective HIV-vaccine should induce broadly neutralizing antibodies (bNAbs) targeting the viral envelope glycoprotein, which is challenged by the low frequencies of bNab precursor B cells. Pre-clinical studies have shown the ability of the BG505 SOSIP.GT1.1 gp140 (GT1.1) vaccine to prime bNAb precursor B cells, including those targeting the CD4-binding site. Here, we report…

Vaccine Combining Slow-Delivery and Follicle-Targeting Improve Humoral and Germinal Center Responses

Background: Vaccines generate humoral immunity by activating antigen-specific helper T cells and B cells, which cooperate in germinal centers (GCs) to generate high-affinity antibodies. To provide antibody-based protection, an HIV vaccine will likely need to induce broadly neutralizing antibodies (bnAb). To date, identified bnAbs exhibit unusual features like extensive and improbable mutations and lengthy CDR3s;…